Background: Hepatitis C virus (HCV) infection is a global medical problem. The current
standard of care for chronic hepatitis C (CHC) is pegylated interferon plus ribavirin
therapy, but this treatment is expensive, has significant side effects and, at best, is only
50% effective. Silymarin, the main active ingredient of milk thistle, is a natural
antioxidant that is used by patients with CHC, although its efficacy for decreasing HCV
levels or ameliorating CHC remains uncertain. HCV infection is associated with
increased hepatic oxidative stress, and one of the antioxidant enzymes which protects
cells against this stress is heme oxygenase-1 (HO-1). Methods: We investigated the
effects of silymarin on HCV and HO-1 gene expression in wild type Huh-7 cells, as well
as two HCV replicon cell lines, CNS3 and 9-13 cells. Results: Silymarin (100 and 200
μM) down-regulated HCV core mRNA (by 20% - 36%) and protein (by 30%-60%) in
CNS3 cells. In contrast, silymarin did not decrease HCV NS5A mRNA or protein
expression in treated 9-13 cells; in fact, it increased NS5A mRNA levels by two fold.
HO-1 mRNA was up-regulated (60%-400%) by silymarin in Huh-7, CNS3 and 9-13
cells. To explore the mechanism by which silymarin up-regulates HO-1 mRNA, we
measured the levels of Bach1 and Nrf2 transcription factors. Bach1 and Nrf2 mRNA
levels were not affected by silymarin treatment in Huh-7 cells. In CNS3 and 9-13 cells,
there was no clear relationship between silymarin-induced changes in Bach1 and Nrf2
and the induction of HO-1 mRNA. Silymarin do not down-regulate HCV core protein
through the Jak-Stat pathway. Conclusions: Silymarin significantly down-regulates HCV
core mRNA and protein in CNS3 cells. The effect of silymarin to down-regulate HCV
core is not related to changes in the Jak-Stat signaling pathway. The levels of the
antioxidant enzyme HO-1 are up-regulated by silymarin, but the precise mechanism by
which silymarin up-regulates HO-1 mRNA levels in these cell lines remains unknown.
These and other recent results suggest that silymarin is of benefit in CHC, although
prospective, randomized, controlled-trials are needed to be certain.
| Identifer | oai:union.ndltd.org:UDLA-Thesis/oai:ciria.udlap.mx:u-dl-a/tesis/2032050415981 |
| Date | 13 July 2007 |
| Creators | Bonifaz Peña, Vania Elvira |
| Contributors | Dr. José Luis Sánchez Salas, Dr. Solon Javier Garcés Eisele, Dr. José Daniel Lozada Ramírez |
| Publisher | Universidad de las Américas Puebla |
| Source Sets | UDLA-Thesis |
| Language | English |
| Detected Language | English |
| Type | Electronic Thesis or Dissertation, Tesis |
| Format | application/pdf, text/html |
| Coverage | Maestría |
Page generated in 0.0021 seconds